

## December 30, 2015

FROM: Schulman IRB ("Schulman" or the "Board")

**TO:** All sites that receive Schulman approval to conduct this protocol

**SUBJECT:** Recruitment/Study-Related Material

**IRB NO.:** 201506061;

**SPONSOR:** Eli Lilly and Company

**PROTOCOL NO.:** I1F-MC-RHBV

**CONTACT:** 

The following item was reviewed by Expedited Review, as referenced below, and received a decision of

Approved for use ONLY in its entirety

Material Type: Ad-Print Material Item#: MA1510092-0

**Description :** Site & Patient Facing Tools Ad\_v1\_10Dec2015 - 4

Submitted By:SponsorReceived Via:Initial Sub.Received Date:12/18/2015Review Date:12/29/2015

Approved and/or Acknowledged Recruitment/Study-Related materials should not be used or distributed to study subjects until you have received an approval letter from Schulman to conduct this study.

Acknowledged material includes, but is not limited to, copyrighted documents, some subject instructions, standardized questionnaires, etc.

Any variation of approved or acknowledged materials (other than contact information) must be resubmitted for review.

PLEASE REFERENCE MATERIAL ITEM NUMBER MA1510092-0 ON ALL CORRESPONDENCE

WebPortal/Paperless



## Ankylosing Spondylitis Research Study

Researchers are testing a study medication for AS.

- Study-related care from a local doctor
- · Investigational medication
- Possible compensation for time and travel

Find out if you qualify to participate.



## call XXX.XXXXXXX or visit XXXXXX.com